SSG trial: 3 years vs 1 year of adjuvant GLIVEC treatment1
|Study objective||Determine impact on RFS and OS of 3 years vs 1 year of adjuvant GLIVEC treatment in patients at substantial risk of recurrence1|
|Study description||GLIVEC at 400 mg/day for 12 months vs 36 months after surgical resection of primary KIT+ GIST1|
|Inclusion criteria||Resected patients with confirmed KIT+ GIST and one of the following1:
|Median follow-up||54 months1|
|Primary end point||RFS, defined as the time from date of randomization to the date of recurrence or death from any cause1|
|Secondary end points||OS, safety2|
References: 1. Glivec® (imatinib) summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited. 2. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265-1272.
Reference: 1. Glivec® (imatinib) summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited.